1st Quarter - Report

BIOGEN for BIOGEN

Firm
Client
Income
—
Expenses
$290,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

HR 1 -- Repatriation, deferral and R&D credit issues

LobbyistCovered position, as disclosed
ADAM GLUCK Staff, Senate HELP Committee
KATHLEEN TREGONING Staff, House Ways and Means Committee

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1 (111th)

Medicare/Medicaid MMM

Advocacy for appropriate reimbursement and payment rates for biologics under the Medicare and Medicaid programs.

LobbyistCovered position, as disclosed
ADAM GLUCK Staff, Senate HELP Committee
KATHLEEN TREGONING Staff, House Ways and Means Committee

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing stregnth and value of intellectual property for biotechnology, especially related to damages provisions, inequitable conduct, and post-grant/second window.

LobbyistCovered position, as disclosed
ADAM GLUCK Staff, Senate HELP Committee
KATHLEEN TREGONING Staff, House Ways and Means Committee

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1260 (111th), S. 515 (111th)

Health Issues HCR

1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation. 3) S. 301-- Advocating for reasonable gift disclosure requirments that provide appropriate transperancy and protects proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and opposed to using such research for cost containment or denial of coverage.

LobbyistCovered position, as disclosed
ADAM GLUCK Staff, Senate HELP Committe
KATHLEEN TREGONING Staff, House Ways and Means Committee

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1427 (111th), H.R. 1548 (111th), S. 301 (111th), H.R. 1 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.